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Abstract
Background: After curative treatment for breast cancer women frequently attend scheduled follow-up
examinations. Usually the follow-up is most frequent in the first 2–3 years (2–4 times a year); thereafter
the frequency is reduced to once a year in most countries. Its main aim is to detect local disease recurrence,
or a second primary breast cancer, but also to provide information and psychosocial support. However,
the cost-effectiveness of these frequent visits is under much debate, leading to a search for less intensive
and more cost-effective follow-up strategies.
In this paper the design of the MaCare trial is described. This trial compares the cost-effectiveness of four
follow-up strategies for curatively treated breast cancer patients. We investigate the costs and effects of
nurse-led telephone follow-up and a short educational group programme.
Methods/design: The MaCare trial is a multi centre randomised clinical trial in which 320 breast cancer
patients are randomised into four follow-up strategies, focussed on the first 18 months after treatment: 1)
standard follow-up; 2) nurse-led telephone follow-up; 3) arm 1 with the educational group programme; 4)
arm 2 with the educational group programme. Data is collected at baseline and 3, 6, 12 and 18 months after
treatment. The primary endpoint of the trial is cancer-specific quality of life as measured by the global
health/QoL scale of the EORTC QLQ-C30. Secondary outcomes are perceived feelings of control, anxiety,
patients' satisfaction with follow-up and costs. A cost-effectiveness analysis will be performed from a
societal perspective.
Discussion: Reduced follow-up strategies for breast cancer have not yet been widely applied in clinical
practice. Improvement of psychosocial support and information to patients could lead to a better
acceptance of reduced follow-up. The MaCare trial combines a reduced follow-up strategy with additional
psychosocial support. Less frequent follow-up can reduce the burden on medical specialists and costs. The
educational group programme can improve QoL of patients, but also less frequent follow-up can improve
QoL by reducing the anxiety experienced for each follow-up visit. Results of the trial will provide
knowledge on both costs and psychosocial aspects regarding follow-up and are expected in 2009.
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Background
With an estimated 1.15 million new cases worldwide each
year, breast cancer is by far the most frequent cancer in
women. Because of its high incidence and relatively good
prognosis, breast cancer is also the most prevalent cancer
in the world today [1]. After curative treatment for breast
cancer women frequently attend scheduled follow-up
examinations. Usually the follow-up is most frequent in
the first 2–3 years (2–4 times a year); thereafter the fre-
quency is reduced to once a year in most countries. The
main objective of these examinations is to detect local dis-
ease recurrence or a second primary breast cancer in an
early stage, hoping that this may increase the chances of
cure. Follow-up should also provide information and psy-
chological support. Another aim is to collect data on late
effects of surgery, radiotherapy and chemotherapy for
audit or research and to provide feedback to physicians
[2,3]. However, there is much debate whether the objec-
tives of breast cancer follow-up are adequately met in cur-
rent practice [4,5]. Schapira (1993) reported that the early
frequent outpatient clinic visits with only physical exami-
nation and an annual mammography do not improve
early detection of recurrence or overall survival [6]. Since
then, several studies have investigated the effect of the fre-
quency [7] and intensity [8,9] of follow-up on overall sur-
vival, without finding evidence supporting the necessity
of frequent or intensive follow-up. Furthermore, instead
of providing psychosocial support, it has been demon-
strated that the outpatient clinic visit may induce anxiety
because of the risk of detecting tumour relapse [10,11].
Although the current frequent follow-up strategies thus
seem to miss their most important goals, they do depend
heavily on expensive and scarce specialised knowledge for
routine history taking and physical examination. Finan-
cial constraints have forced oncologists and policy makers
to search for alternative and cost-effective follow-up strat-
egies. Studies on follow-up by the general practitioner,
patient-initiated or nurse-led follow-up or contact by tele-
phone showed no difference in time to detection of recur-
rence or patients perceived quality of life (QoL) [12-16].
Nevertheless, these reduced strategies have not yet been
widely accepted and applied in clinical practice. This may
on the one hand be ascribed to the perception of many
medical specialists that most patients need reassurance
and psychosocial support, and on the other hand to the
false expectations of many patients that frequent follow-
up will result in a better overall survival [17]. Improve-
ment of the psychosocial support and education of the
patients may lead to a better acceptance of both patients
and medical specialists of a reduced follow-up policy. A
number of studies have been performed using various
group intervention formats for breast cancer patients to
provide psychosocial support. However, most interven-
tions mainly focussed on intensive psychological support
(10 sessions or more), showing varying results and often
high refusal rates [18].
No trials have been performed that combine a reduced
follow-up policy in the first 2 years with an acceptable
strategy to provide information and education. For this
reason, two interventions for early breast cancer follow-up
were developed for the study that is discussed in this
paper; nurse-led telephone follow-up and a short educa-
tional group programme (EGP). The primary aim of the
so-called MaCare trial (Mamma carcinoma and afterCare)
is to investigate the impact of these interventions on can-
cer-specific QoL and costs and thus to determine which of
these follow-up strategies is the most cost-effective. This
paper reports on the methodological design of the trial as
well as the contents of the interventions and the economic
evaluation.
Methods/Design
Study design
The MaCare trial is a multi centre randomised trial, in
which breast cancer patients who are treated with curative
intent are randomised between four follow-up strategies
(see figure 1):
1) Follow-up as usual; 5 outpatient clinic visits in the first
18 months (at 3, 6, 9, 12, and 18 months), with a mam-
mography at one year.
2) Nurse-led telephone follow-up; a mammography at
one year combined with an outpatient clinic visit, and tel-
ephone interviews by a breast care nurse (BCN) or nurse
practitioner (NP) at the same time points as during the
usual follow-up (i.e. 3, 6, 9 and 18 months).
3) Similar to arm 1, combined with the EGP.
4) Similar to arm 2, combined with the EGP.
After 18 months patients return to the current follow-up
strategy, i.e. follow-up once a year.
Setting
The trial is carried out in seven hospitals and two radio-
therapy clinics located in the south of The Netherlands.
Medical specialists working in the participating centres
have been recruiting patients since July 2005 and will con-
tinue recruitment until approximately September 2007.
Follow-up as usual takes place in the hospital where sur-
gery and chemotherapy were performed, alternating
between the surgeon, medical oncologist and radiation
oncologist. The telephone follow-up is performed by the
nurse practitioner (NP) or breast care nurse (BCN) work-
ing at this hospital. An NP is a registered nurse who has
acquired (at masters level) the expert knowledge base,BMC Cancer 2007, 7:1 http://www.biomedcentral.com/1471-2407/7/1
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complex decision-making skills and clinical competencies
for expanded practice. The BCN is a qualified nurse who
has had specialist training in breast care and who guides
the patient throughout treatment. In this paper the term
BCN is used and refers to both types of nurses. The EGP is
held at cancer information centres. These centres are spe-
cialised in providing support to (ex-)cancer patients and
their relatives through education and organising activities.
Selecting participants from multiple centres and locations
in the Netherlands allows us to include a representative
selection of breast cancer patients. Participation is volun-
tary and after written informed consent is obtained. Prior
to the start of the study the protocol was approved by the
Medical Ethical Committee of MAASTRO Clinic. Further-
more, all participating centres signed a declaration on
local feasibility before inclusion of their first patient,
according to the Dutch law and regulations.
Study population
Selection of participants
Patients are recruited and included within 6 weeks after
completion of treatment with curative intent by the med-
ical specialist of the last treatment modality. Eligibility cri-
teria are summed up in table 1. If eligible, the medical
specialist introduces the MaCare trial to the patient and
gives her a detailed information sheet. Within two weeks,
the research assistant contacts the patient to explain the
aim and implications of the trial again. Eligibility criteria
are checked once more and the research assistant asks
whether the patient wants to participate.
Study design of the MaCare trial 'Improving the quality and efficiency of follow-up after curative treatment for breast cancer' Figure 1
Study design of the MaCare trial 'Improving the quality and efficiency of follow-up after curative treatment for breast cancer'. F-
up = follow-up; R = randomisation; EGP = educational group programme; BCN = breast care nurse; NP = nurse practitioner; 
N = number of patients
Breast cancer patients without distant metastases, 
within 6 weeks after treatment
Surgery +/- radiotherapy +/- chemotherapy; included 
by last treating medical specialist
Medical oncologist Radiation oncologist Surgeon
1. F-up as usual 2. Telephone f-up by BCN/ NP
4. Telephone f-up by BCN/ NP 
and EGP
3. F-up as usual
and EGP
R
N = 80
N = 80 N = 80
N = 80BMC Cancer 2007, 7:1 http://www.biomedcentral.com/1471-2407/7/1
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Non-participants
Patients who are eligible for inclusion but not interested
in participation are asked to fill out the same baseline
questionnaires (see outcome parameters) as participants.
By assessing whether there are differences between partic-
ipants and non-participants the external validity of the
study results can be determined.
Sample size calculations
The primary outcome measure is cancer specific QoL at 12
months after randomisation, measured by the global
health/QoL scale of the EORTC QLQ-C30. A baseline
score of 64 with a standard deviation of 17 [19,20] is con-
sidered as a starting point. In an analysis of the clinical sig-
nificance of changes in QoL, Osoba et al (1998) showed
that patients judge a change between 5–10 to be small,
between 10–20 to be moderate, and more than 20 to be
large [21]. Consequently, we considered a change smaller
than 5 points to be no change. To show that QoL of
patients in arms 2 and 4 (telephone follow-up) is at least
similar to patients in arm 1 and 3 (usual follow-up) with
a power of 80% and a significance level of 0.05, the
required number of patients per group is 80. With these
320 patients an improvement in QoL, by adding the EGP
compared to no EGP, of 10 points with a power of 0.95
and a significance level smaller than 0.01 can be detected.
A dropout rate of 10% is accounted for in these calcula-
tions.
Randomisation
After written informed consent and completion of the
baseline questionnaire, randomisation by minimisation
is performed by the Comprehensive Cancer Centre Lim-
burg. Patients are pre-stratified by treatment modalities
and hospital. After randomisation, the research assistant
contacts the patient and informs her about the assigned
study-arm, thus whether she will receive standard or tele-
phone follow-up and whether she will be invited to join
the EGP.
Interventions
Usual care
The first study arm, the standard arm, consists of follow-
up as described in the Dutch guidelines. After treatment,
the patient has an outpatient clinic visit with the medical
specialist or BCN every 3 months during the first year,
every 6 months during the second year, and thereafter
once a year until at least 5 years. Mammography is taken
once a year.
Nurse-led telephone follow-up
In study arms 2 and 4 a mammography is taken once a
year, which is combined with a visit to the medical oncol-
ogist, the surgeon, BCN or the radiation oncologist. At the
other regular follow-up times (i.e. at 3, 6, 9, and 18
months), the BCN has a telephone interview with the
patient. The telephone interview is done by open discus-
sion and a semi structured questionnaire, including
screening for physical – especially loco regional – and psy-
chosocial symptoms, and compliance to hormonal ther-
apy. Data on the side effects of treatment are also collected
during the interview. Furthermore, the BCN informs
about general well being of the patient, her family-life,
relationships and work reintegration. When the patient
does not feel reassured an additional appointment is
made for her to come to the hospital. The telephone fol-
low-up is mainly meant to reduce the workload of medi-
cal specialists, with possible reduction of costs, but could
also influence QoL as a result of a reduction of stressful
visits to the outpatient clinic [11]. To adequately perform
the telephone interview, all participating BCNs attained a
training, specifically developed for this study. In this train-
ing nurses are informed on the most recent developments
in breast cancer treatment and follow-up, develop a semi-
structured questionnaire for support during the interview,
and practice their telephone communication skills with a
breast cancer patient.
Educational Group Programme
In arms 3 and 4 of the study, the patient and their partner
(or close friend or family member) are invited to partici-
pate in the Educational Group Programme (EGP) within
three months after treatment. The basic theory underlying
the EGP is the transaction process theory of stress [22].
The group-format programme focuses on the first two
stages of the transaction process theory of stress, the pri-
mary and secondary appraisal. The EGP therefore consists
of two interactive group sessions of 2,5 hours of patient
education. In the first session, which addresses the pri-
mary appraisal, a BCN provides information on possible
side effects of the different treatments and issues such as
prostheses, exhaustion, hereditary issues and financial
Table 1: Study inclusion and exclusion criteria
Inclusion criteria
• Female patients with breast cancer without distant metastases
• WHO performance scale 0–2
• Treated with curative intent (i.e. lumpectomy or mastectomy, with or without radiotherapy and/or chemotherapy)
• Treatment completed < 6 weeks prior to randomisation
• Able to speak and read fluently in Dutch
Exclusion criteria
• Participation in another trial, requiring more frequent follow-up
• Medical diseases (treatment-related side-effects, concomitant tumours) requiring frequent follow-upBMC Cancer 2007, 7:1 http://www.biomedcentral.com/1471-2407/7/1
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consequences. Also, signs and symptoms of recurrences
are discussed. A health care psychologist concentrates on
psychological consequences, like anxiety, depression and
changed family role patterns. The second session focuses
on the second appraisal, i.e. information is provided on
possible coping strategies and actions that could be
undertaken when symptoms occur. Furthermore, infor-
mation on the various health care workers and additional
interventions is given. Discussions are stimulated by the
speakers, addressing issues such as how to deal with anxi-
ety, mood changes and changes in relationships. In this
way, patients and their partners are stimulated to be alert
to symptoms, and to enhance self-efficacy in adopting one
of the proposed actions or coping strategies. It is expected
that this will lead to a better QoL. During the second ses-
sion a volunteer from the Dutch Breast Cancer Association
presents regional activities available for participants. The
EGP is completed with a relaxation exercise. After the two
sessions, participants receive a small booklet encompass-
ing the topics discussed in the programme. The BCN and
health care psychologist use standardised presentations,
so that the EGPs given during the time of this study are as
similar as possible. Furthermore, by using standard pres-
entations, different teams can lead the EGP and the pro-
gramme will be easily transferable to other settings.
Primary and secondary outcome measures
Primary outcome measure
The primary domain for improvement for both interven-
tions in the trial is cancer-specific QoL. Cancer-specific
QoL is measured by the QoL scale of the European Organ-
isation for Research and Treatment of Cancer (EORTC)
QLQ-C30. The EORTC QLQ-C30 has a validated Dutch-
language version available [23].
Secondary outcome measures
Secondary outcome measures are perceived behavioural
control, anxiety, patients' satisfaction with follow-up,
generic health-related quality of life and societal costs.
Perceived behavioural control is measured by the Dutch
version of the Mastery Scale [24]. A question whether the
patient is experiencing emotional support from partner (if
applicable) is added. Anxiety is measured by the validated
Dutch version of the State-Trait Anxiety Inventory (STAI)
[25]. Patients' satisfaction with follow-up will be assessed
using the validated Patient Satisfaction Questionnaire –
NL (PSQ-NL) [26]. Generic health-related quality of life is
measured by the EuroQol-5D (EQ-5D) [27].
Societal costs are determined by the hospital information
systems and prospective cost-diaries. More details on the
costs are provided in the economic evaluation section.
Time schedule
Patients complete questionnaires at baseline, and at 3, 6,
12 and 18 months intervals. Costs-diaries are filled out by
the patients over a four week period, at the same time
points. The questionnaires and cost-diaries are sent by
mail. If not returned within 14 days, patients are con-
tacted by the research assistant and are asked to continue
participation.
Statistical analyses
To evaluate differences in QoL outcome between the
study arms, the data will be analysed using a multivariate
linear regression model. In this model both the EGP factor
and the telephone factor will be taken into account. In
addition, variables such as age, hospital treatment, and
experienced support of a partner, will be brought into the
model. The procedure will be performed 4 times as QoL is
assessed at 3, 6, 12 and 18 months. Differences in satisfac-
tion with care, perceived behavioural control and anxiety
will be analysed in the same way. Participation at group
meetings will be analysed using logistic regression mod-
els. Differences in medical consumption will be evaluated
using a multivariate linear regression model. Subgroup
analysis will be performed to identify specific patient
characteristics that could predict the optimal follow-up
strategy for the individual patient. Data will be analysed
according to the intention-to-treat principle.
The number of recurrences is expected to be very low with
a follow-up of 18 months [28]. Statistical analysis of the
difference in time-to-detection per group will therefore be
limited to descriptive statistics.
Economic evaluation
Parallel to the trial an economic evaluation will be per-
formed, comparing the costs and effects of each separate
follow-up strategy, in order to determine the most cost-
effective follow-up. The cost-effectiveness comparison
thus includes four different strategies corresponding to
the four study-arms. The cost-effectiveness ratio(s) will be
expressed as the incremental cost per quality-adjusted life
year (QALY). In order to be able to construct a QALY, the
scores on the 5 dimensions of the EuroQol [29] are used.
The cost-effectiveness analysis is performed from a soci-
etal perspective. Sensitivity analyses will subsequently be
performed on several variables. For future costs and effec-
tiveness data, a discount rate of 4% will be handled. In
order to quantify the uncertainty surrounding the costs
and effectiveness results, bootstrap analyses will be per-
formed.
The cost-analysis from a societal perspective includes all
health care costs and costs outside the health care sector.
The cost-analysis will be performed by means of the
micro-costing method, whereby a detailed inventory ofBMC Cancer 2007, 7:1 http://www.biomedcentral.com/1471-2407/7/1
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the resource use per patient will take place [30]. Costs are
calculated by multiplying resource utilisation with the
cost-price per unit. Health care costs refer to hospital costs
and costs of other health care facilities. Hospital costs con-
sist of personnel, material, capacity costs and overhead
associated with the four programmes and costs of (sched-
uled and unscheduled) outpatient hospital visits, tele-
phone interviews and medical services (e.g. laboratory
tests, bone scans, etc.). Most of these costs are estimated
by using existing resource registration systems and availa-
ble cost prices through the financial departments of the
participating centres. In case true cost prices are not read-
ily available in all participating centres the existing cost-
prices of the University Hospital Maastricht or official
directive prices are used [31]. Costs of telephone follow-
up consist of personnel costs of the BCN and telephone
costs. Costs associated with the EGP primarily consist of
the personnel costs. Other health care costs include costs
of visits to the general practitioner, medication, psycho-
logical and/or psychiatric (emergency) care.
Costs outside the health care sector refer to out-of-pocket
expenditures and productivity costs due to reductions in
paid work and/or domestic activities. These costs are
determined by a prospective cost diary, which is filled in
by the patient at baseline, and thereafter at 4 time points
(3, 6, 12, and 18 months after treatment) for a period of 4
weeks. Productivity losses due to absence from work are
estimated by means of the friction cost method [31,32]. In
case of domestic or other unpaid activities, shadow prices
will be used.
Discussion
Current frequent follow-up is not meeting its intended
aims, but does raise the burden on medical specialists,
leading to high medical costs. Although studies investigat-
ing reduced follow-up have shown that there is no differ-
ence in time to detection of recurrence and patients
perceived QoL, reduced follow-up has not yet been widely
accepted and applied. Medical specialist may feel that
patients need constant reassurance and patients have the
false expectation that frequent follow-up will improve
survival [17]. Improvement of psychosocial support and
information to patients could lead to a better acceptance
of reduced follow-up. The trial reported in this paper com-
bines these two aspects. By performing an economic eval-
uation parallel to the trial, the ultimate aim is to find an
alternative and more cost-effective follow-up strategy. We
expect the educational group programme to help breast
cancer patients and their partners in dealing effectively
and efficiently with the consequences of a recent diagno-
sis and treatment of a potentially fatal disease. This
increase in perceived behavioural control is expected to
improve QoL. The nurse-led telephone calls are expected
to render visits to the outpatient clinic superfluous, which
may subsequently reduce the anxiety experienced by
patients for each follow-up visit. Looking at costs, the tel-
ephone follow-up is expected to be cost-saving, due to
fewer visits to the medical specialist. The EGP is expected
to result in a slight cost-increase per patient in the first fol-
low-up year, as compared to standard follow-up. How-
ever, due to the expected increase in QoL it may yield 1)
reduced health care costs and 2) possibly lower costs due
to a reduction in productivity losses.
The close cooperation with many centres enables us to
reach a representative study population of women treated
for primary breast cancer and enhances the generalisabil-
ity of the trial results. In addition, BCNs are systematically
trained to perform telephone follow-up and the EGP is
based on standardised presentations. If one or both inter-
ventions appear to be successful, they are easily transfera-
ble to other settings. Finally, results may be extended to
other cancer patients, but a further study would be
required.
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